Medication-Assisted Treatment (MAT) Regulation

Current understanding

Federal rules governing practitioner eligibility, prescribing, dispensing, and pharmacy delivery of controlled substances used in medication-assisted treatment (MAT) for opioid use disorder — primarily buprenorphine and methadone. Framework is set by the SUPPORT Act of 2018 and the Restoring Hope for Mental Health and Well-Being Act of 2022, with DEA implementing regulations that affect which clinicians can treat OUD patients and how pharmacies may deliver MAT drugs to opioid treatment programs and patients.

Evidence log

• 2026-07-16 — To direct the Director of the Bureau of Prisons to provide medication assisted treatment for opioid addiction to certain women.: cross-connection with mat-opioid-treatment-bop-women: HR9756 applies the broader federal MAT regulatory framework to a specific carceral subpopulation (women in BOP custody), linking correctional healthcare policy to general MAT access rules. (novelty: 2)
• 2025-02-20 — Fatal Overdose Reduction Act of 2025: cross-connection with fatal-overdose-reduction-act: Health Engagement Hubs would be a primary Medicaid-financed delivery site for medications for opioid use disorder (MAT/MOUD), linking the demonstration to federal MAT regulatory frameworks. (novelty: 3)
• 2026-06-09 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment: cross-connection with drug-scheduling-controlled-substances: MAT medications like buprenorphine are CSA-scheduled controlled substances, so DEA MAT rules operate within the broader controlled substances regulatory framework. (novelty: 2)

Open questions

Related